Lilly Announces Positive Type 2 Diabetes Data

mia.burns

Presented at 49th EASD Annual Meeting Show Treatment with ’s Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
Improvements in several indicators of management, including perceptions about hyperglycaemia and weight, observed for investigational GLP-1 receptor agonist

BARCELONA, Spain, Sept. 26, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced patient-reported health outcomes from a Phase III clinical trial of dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for 2 diabetes. These results will be presented at the 49th European Association for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Spain.

In addition to reductions in HbA1c (hemoglobin A1c) levels and weight at 26 and 52 weeks with dulaglutide 1.5 mg,1 dulaglutide-treated patients reported significant, positive improvements compared to baseline across several patient-reported indicators of diabetes management, measured using validated questionnaires, including:

    satisfaction with treatment and rates of perceived hyperglycaemia as measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ);
    weight-related self-perception (Impact of Weight on Self-Perception (IW-SP) and Ability to Perform Physical Activities of Daily Living Questionnaires (APPADL)); and
    perceived current health status (EuroQoL 5-Dimension Questionnaire (EQ-5D)).2

“Patients’ perception of how diabetes treatment may affect their lives is an important consideration when choosing a medication. We are pleased that in this study, patients treated with dulaglutide reported improvements in several patient-reported outcome measures,” said Gwen Krivi, Ph.D., vice president, Lilly Diabetes product development. “These results, coupled with dulaglutide’s positive clinical data, suggest that, if approved…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS